AZN
Price
$172.60
Change
+$4.15 (+2.46%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
261.25B
8 days until earnings call
Intraday BUY SELL Signals
BIIB
Price
$253.84
Change
+$12.86 (+5.34%)
Updated
Oct 22 closing price
Capitalization
37.51B
6 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AZN vs BIIB

AZN vs BIIB Comparison Chart in %
View a ticker or compare two or three
VS
AZN vs. BIIB commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AZN is a StrongBuy and BIIB is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for AZN with price predictions
Oct 22, 2026

AZN in upward trend: 10-day moving average broke above 50-day moving average on October 21, 2026

The 10-day moving average for AZN crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 62%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on AZN as a result. In 47 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.

The Moving Average Convergence Divergence (MACD) for AZN just turned positive on October 15, 2026. Looking at past instances where AZN's MACD turned positive, the stock continued to rise in 25 of 42 cases over the following month. The odds of a continued upward trend are 60%.

AZN moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +6.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where AZN advanced for three days, in 191 of 338 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 50-day moving average for AZN moved below the 200-day moving average on September 18, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.

AZN broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 17 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. AZN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.194) is normal, around the industry mean (-3.019). P/E Ratio (24.993) is within average values for comparable stocks, (21.251). Projected Growth (PEG Ratio) (1.168) is also within normal values, averaging (5.738). Dividend Yield (0.025) settles around the average of (0.041) among similar stocks. P/S Ratio (4.148) is also within normal values, averaging (4.033).

The Tickeron PE Growth Rating for this company is 65 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
a Summary for BIIB with price predictions
Oct 22, 2026

BIIB's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for BIIB turned positive on October 13, 2026. Looking at past instances where BIIB's MACD turned positive, the stock continued to rise in 39 of 60 cases over the following month. The odds of a continued upward trend are 65%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on BIIB as a result. In 50 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.

Following a +4.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIIB advanced for three days, in 166 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.

The Aroon Indicator entered an Uptrend today. In 122 of 197 cases where BIIB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.

Bearish Trend Analysis

The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIIB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.

BIIB broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 6 (best 1 - 100 worst), indicating outstanding price growth. BIIB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.990) is normal, around the industry mean (-3.019). P/E Ratio (44.690) is within average values for comparable stocks, (21.251). Projected Growth (PEG Ratio) (2.357) is also within normal values, averaging (5.738). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (3.189) is also within normal values, averaging (4.033).

The Tickeron SMR rating for this company is 84 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIIB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.

FUNDAMENTALS RATINGS
AZN vs BIIB: Fundamental Ratings
AZN
BIIB
OUTLOOK RATING
1..100
7325
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
80
Overvalued
PROFIT vs RISK RATING
1..100
17100
SMR RATING
1..100
4484
PRICE GROWTH RATING
1..100
416
P/E GROWTH RATING
1..100
653
SEASONALITY SCORE
1..100
2050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AZN's Valuation (56) in the Pharmaceuticals Major industry is in the same range as BIIB (80) in the Biotechnology industry. This means that AZN’s stock grew similarly to BIIB’s over the last 12 months.

AZN's Profit vs Risk Rating (17) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (100) in the Biotechnology industry. This means that AZN’s stock grew significantly faster than BIIB’s over the last 12 months.

AZN's SMR Rating (44) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (84) in the Biotechnology industry. This means that AZN’s stock grew somewhat faster than BIIB’s over the last 12 months.

BIIB's Price Growth Rating (6) in the Biotechnology industry is somewhat better than the same rating for AZN (41) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew somewhat faster than AZN’s over the last 12 months.

BIIB's P/E Growth Rating (3) in the Biotechnology industry is somewhat better than the same rating for AZN (65) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew somewhat faster than AZN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AZNBIIB
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
75%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
48%
Bearish Trend 1 day ago
71%
Momentum
ODDS (%)
Bullish Trend 1 day ago
59%
Bullish Trend 1 day ago
59%
MACD
ODDS (%)
Bullish Trend 1 day ago
60%
Bullish Trend 1 day ago
65%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
55%
Bullish Trend 1 day ago
61%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
56%
Bullish Trend 1 day ago
65%
Advances
ODDS (%)
Bullish Trend 8 days ago
57%
Bullish Trend 3 days ago
59%
Declines
ODDS (%)
Bearish Trend 4 days ago
46%
Bearish Trend 15 days ago
68%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
54%
Bearish Trend 1 day ago
70%
Aroon
ODDS (%)
N/A
Bullish Trend 1 day ago
62%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (AZN: $168.45 vs. BIIB: $253.84)
Brand notoriety: AZN and BIIB are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: AZN: 61% vs. BIIB: 221%
Market capitalization -- AZN: $261.25B vs. BIIB: $37.51B
AZN [@Pharmaceuticals: Major] is valued at $261.25B. BIIB’s [@Pharmaceuticals: Major] market capitalization is $37.51B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $4.8K to $1.13T. The average market capitalization across the [@Pharmaceuticals: Major] industry is $206.81B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AZN’s FA Score shows that 1 FA rating(s) are green while BIIB’s FA Score has 2 green FA rating(s).

  • AZN’s FA Score: 1 green, 4 red.
  • BIIB’s FA Score: 2 green, 3 red.
According to our system of comparison, AZN is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AZN’s TA Score shows that 5 TA indicator(s) are bullish while BIIB’s TA Score has 4 bullish TA indicator(s).

  • AZN’s TA Score: 5 bullish, 4 bearish.
  • BIIB’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, AZN is a better buy in the short-term than BIIB.

Price Growth

AZN (@Pharmaceuticals: Major) experienced а +3.96% price change this week, while BIIB (@Pharmaceuticals: Major) price change was +7.86% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.73%. For the same industry, the average monthly price growth was -4.97%, and the average quarterly price growth was +5.45%.

Reported Earning Dates

AZN is expected to report earnings on Oct 30, 2026.

BIIB is expected to report earnings on Oct 28, 2026.

Industries' Descriptions

@Pharmaceuticals: Major (+0.73% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

View a ticker or compare two or three
AZN
Daily Signal:
Gain/Loss:
BIIB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

AZN and

Correlation & Price change

A.I.dvisor indicates that over the last year, AZN has been loosely correlated with BIIB. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if AZN jumps, then BIIB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AZN
1D Price
Change %
AZN100%
+2.45%
BIIB - AZN
48%
Loosely correlated
+5.34%
GILD - AZN
39%
Loosely correlated
+2.36%
GSK - AZN
26%
Poorly correlated
+2.38%
MRK - AZN
26%
Poorly correlated
-1.76%
NVS - AZN
25%
Poorly correlated
+1.52%
More

BIIB and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AZN. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AZN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
+5.34%
AZN - BIIB
49%
Loosely correlated
+2.45%
AMGN - BIIB
48%
Loosely correlated
+2.04%
PFE - BIIB
48%
Loosely correlated
+1.91%
MRK - BIIB
46%
Loosely correlated
-1.76%
ABBV - BIIB
41%
Loosely correlated
+0.14%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SBRA19.600.70
+3.70%
Sabra Health Care REIT
CBLL27.400.26
+0.96%
CERIBELL INC
EBAY122.04-0.86
-0.70%
eBay
GRRR8.14-0.07
-0.85%
Gorilla Technology Group
ACH0.21-0.01
-3.66%
Accendra Health Inc